Hero MotoCorp (NSE: HEROMOTOCO) May dispatches rise to 5.7 lakh units as VIDA and exports sharpen growth story
Read More Pharma Industry News Biohaven (NYSE: BHVN) deprioritizes BHV-7000 in depression after Phase 2 miss, shifts focus to epilepsy, obesity, and immunology Biohaven ends BHV-7000 depression trials after Phase 2 miss. Find out why it's shifting R&D focus to epilepsy, obesity, and immunology in 2026. byVenkateshDecember 25, 2025